Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley

TipRanks

Thu, Dec 12, 2024, 5:35 AM 1 min read

Morgan Stanley lowered the firm’s price target on Zenas BioPharma (ZBIO) to $35 from $40 and keeps an Overweight rating on the shares. The firm updated its model following Zenas’ recent announcement to not progress obexelimab to Phase 3 for warm autoimmune hemolytic anemia, but argues that current levels are “un-demanding” as Zenas heads towards data in 2025 that will address obexelimab’s competitive potential.

Pick the best stocks and maximize your portfolio:

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on ZBIO: